PROTIA INC.

PROTIA INC.

KKRX:303360
2,665.00
KRW
-65.00
(-2.38%)
284.10EPS
9.14P/E
50.23BMarket Cap
Mar 23Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
408.75
220.75
322.63
353.7
455.58
450.25
545.36
782.27
918.08
Basic EPS, GAAP
-167.67
-72.5
-292.67
-46
74.67
25.33
126.67
231.33
284.43
Free Cash Flow per Basic Share
-157.88
-55.9
-289.12
50.07
62.66
-73.53
13.55
97.22
18.33
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-216.85
426.46
399.11
862.53
949.48
1,218.27
1,356.77
1,589.28
1,720.19
Tangible Book Value per Share
-222.34
421.38
392.89
856.21
943.61
1,211.55
1,350.45
1,583.51
1,714.62
Basic Weighted Avg Shares
12
18
15
17
17
18
19
19
19
Sales/Revenue/Turnover
4,736
3,876
4,906
5,934
7,644
8,228
10,515
15,120
17,749
Operating Margin (%)
5.02
-5.01
-18.37
10.98
13.83
1.99
14.28
24.61
26.27
Depreciation Expense
336
385
399
443
440
447
436
471
489
Net Income, GAAP
-1,943
-1,273
-4,451
-772
1,253
463
2,442
4,471
5,499
Effective Tax Rate (%)
- -
- -
- -
- -
1.13
5.57
- -
- -
3.75
Profit Margin (%)
-41.02
-32.84
-90.71
-13.01
16.39
5.63
23.23
29.57
30.98
Working Capital
-6,013
1,922
-524
8,052
9,510
15,815
17,492
18,943
21,871
LT Debt
53
30
38
206
131
31
119
81
54
Total Equity
-2,834
6,459
6,248
14,525
15,989
23,527
26,207
30,698
33,233
Return on Invested Capital (%)
- -
- -
- -
- -
6.71
0.77
- -
- -
14.6
Return on Capital (%)
- -
- -
- -
- -
8.13
2.37
- -
- -
17.95
Return on Common Equity (%)
- -
- -
-70.05
-7.43
8.21
2.34
9.82
15.72
18.04

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
160
153
172
LT Borrowings
- -
- -
- -
LT Finance Leases
81
48
54
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
19
19
19
Market Capitalization
80,354
56,800
50,231

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
20,870
22,136
23,458
Cash, Cash Equivalents & STI
13,621
13,156
13,936
Accounts Receivable, Net
1,084
1,247
1,587
Inventories
5,110
6,266
7,226
Total Current Liabilities
1,927
2,061
1,587
Payables & Accruals
- -
- -
- -
ST Debt
160
153
172
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
43.65%
17.14%
Free Cash Flow
- -
35.58%
619.1%
Net Income, GAAP
- -
20.51%
83.09%
Sales/Revenue/Turnover
- -
25.8%
43.8%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,166
2,456
2,945
2,948
10,515
2025
2,696
3,845
4,034
4,546
15,120
2026
3,822
5,347
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4.67
51.33
18
52.22
126.67
2025
36.98
40.67
66.71
87.05
231.33
2026
50.64
80
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Kook-Jin Lim
Full Time Employees
113
Sector
Health technology
Industry
Medical specialties
Address
Seoul South Korea
IPO Date
Dec 19, 2018
Business
PROTIA Inc. is a South Korea-based biotechnology and in vitro diagnostics company engaged in the research, development, manufacturing, and commercialization of multiplex diagnostic medical devices, diagnostic reagent kits, and automated analytical instruments for human and veterinary healthcare. Founded in 2000 and headquartered in Seoul, South Korea, the company operates within the healthcare and medical diagnostics sector, serving clinical laboratories, hospitals, diagnostic reference centers, academic research institutes, and veterinary clinics across approximately 80 countries throughout Europe, the Asia-Pacific region, the Americas, and the Middle East. The company provides an extensive portfolio of diagnostic solutions and protein engineering services categorized across multiple clinical segments: human allergy diagnostics, featuring the proprietary PROTIA Allergy-Q series of multiplex line immunoblot assay kits (including Allergy-Q 64, Allergy-Q 96, and high-capacity Allergy-Q 192) for the simultaneous qualitative and semi-quantitative detection of allergen-specific immunoglobulin E (IgE) against inhalant, food, and atopic allergen panels, alongside PROTIA Food IgG assays for food intolerance profiling; veterinary allergy and animal health diagnostics, marketed primarily under the ANITIA and AniCheck brand names, including multi-allergen test panels for companion animals and livestock (such as ANITIA Canine IgE, ANITIA Feline IgE, and ANITIA Equine IgE) as well as rapid bovine colostrum screening kits (such as AniCheck Bovine IgG); rapid point-of-care testing (POCT) devices, including the ImmuneCheck immunochromatographic test line for rapid semi-quantitative measurement of total IgG and IgE levels within minutes without auxiliary equipment; autoimmune disease diagnostics, comprising the PROTIA ANA Profile line immunoassay kits for antinuclear antibody detection; antimicrobial susceptibility testing (AST) systems, headlined by the PROTIA AST platform and the automated Q-AST 192 Pro analyzer utilizing microfluidic biosensors and electrical capacitance measurement technology for rapid determination of minimal inhibitory concentrations; laboratory instrumentation and automated analyzers, including the Q-STATION ELITE fully automated immunoblot processing workstation, the Q-Smart compact strip reader, and the Q-Scan diagnostic interpretation software platform; and custom biotechnology and protein services, offering recombinant protein expression, protein purification, antibody characterization, and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analytical services. In recent corporate developments, the company rebranded from ProteomeTech Inc. to PROTIA Inc. in November 2023 to reflect its strategic alignment as a global in vitro diagnostics provider, following its initial public offering and listing transfer to the KOSDAQ market of the Korea Exchange (Ticker: 303360) in June 2023. PROTIA Inc. has strategically accelerated its international commercial expansion, widening its export network to around 80 countries while obtaining key global regulatory milestones, including European Union In Vitro Diagnostic Medical Devices Regulation (CE-IVDR) certifications for its core multiplex diagnostic kits and instrumentation. Additionally, the company has expanded its commercial portfolio through recent product introductions, including the global launch of the ultra-high-density PROTIA Allergy-Q 192 screening kit, the rollout of the ANITIA Equine IgE diagnostic kit for veterinary allergy panels, and the ongoing commercialization of its rapid phenotypic antimicrobial susceptibility testing platform, the Q-AST 192 Pro.